The annual U.S. cancer screening cost has reached $43.2 billion, with colonoscopies accounting for 55% of that figure. As non-invasive CRC screenings like Cologuard gain popularity, questions arise about the future of colonoscopies. Three physicians shared their views, emphasizing that colonoscopy remains the gold standard for detecting and preventing colon cancer by identifying and removing polyps. While non-invasive tests are becoming more common, they currently lack the sensitivity and specificity of colonoscopy and are not as effective in preventing cancer.
Keep Reading
Add A Comment